

Fermenta Biotech Limited (formerly known as DIL Limited)

CIN: L99999MH1951PLC008485

Regd. Office: A - 1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) - 400 610, Maharashtra, India.

Tel. : +91-22-6798 0888 Fax. : +91-22-6798 0899

Email : info@fermentabiotech.com, Website. : www.fermentabiotech.com



Ref: F.No.:49

February 25, 2022

**Corporate Relations
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai – 400 001**

Dear Sir,

Sub.: Intimation of Investor Relations Presentation – February 2022

Ref: Scrip Code: 506414

Pursuant to the relevant provisions of SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015, we hereby enclose a copy of Investor Relations Presentation for February 2022 for your information.

The said Investor Presentation will thereafter be uploaded on Company's website at www.fermentabiotech.com

This information is submitted to you pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015.

Kindly take the same on records.

Thanking you,

Yours faithfully,
for **FERMENTA BIOTECH LIMITED**
[Formerly known as DIL LIMITED]

A handwritten signature in blue ink, appearing to read 'Srikant N Sharma', is written over a horizontal line.

Srikant N Sharma
Company Secretary
CS Membership No: F3617
A-1501, Thane One, DIL Complex, Ghodbunder Road, Majiwade, Thane (W) 400610

Encl: As above

Factory : Village Takoli, P.O. Nagwain,
Dist. Mandi - 175 121, Himachal Pradesh, India.
Tel. : +91-1905-287246 / 48 / 49
Fax: +91-1905-287250
Email: info@fermentabiotech.com
Website: www.fermentabiotech.com

Factory : Z - 109 B & C, SEZ II, Dahej,
Taluka - Vagara, Dist: Bharuch - 392 130,
Gujarat, India.
Tel. : +91-2641-291440 / 444
Email: info@fermentabiotech.com
Website: www.fermentabiotech.com



FERMENTA BIOTECH LIMITED

Investor Presentation | February 2022



Only manufacturer of
Vitamin D3 in India



Amongst top 3 manufacturers
of Vitamin D3 globally



Global Presence in
60+ countries



Proprietary technology to
manufacture Vitamin D3



55 Years of Vitamin D3
manufacturing experience



2 Manufacturing Plants
registered with US-FDA (FFRN)



DSIR approved
R&D facility



12 new patents filed



Big 4 statutory auditor:
Deloitte



350+ clients across
the globe



Backward integrated



High Return Ratios

Company Overview




- Fermenta Biotech Limited (FBL) (Erstwhile DIL Ltd.) incorporated in 1951 by Dr. DVK Raju, is engaged in development and manufacturing of pharmaceuticals, biotechnology and environmental solutions used across various industries.
- On September 26, 2019, NCLT approved amalgamation of DIL & FBL which consolidated FBL's leadership capabilities backed by DIL's large asset base.
- With a rich history of seven decades FBL has evolved as a key global player in manufacturing of Vitamin D3 in all its formats and has a non-China dependent supply chain.
- FBL manufactures a range of Vitamin D3 variants having an optimal mix between human and animal feed products which have applications across multiple sectors like:


- | | |
|--|-----------------|
| 1. Pharmaceuticals | 4. Animal feed |
| 2. Dietary and nutritional supplements | 5. Veterinary |
| 3. Food and beverage fortification | 6. Rodenticides |

- The company is also involved in manufacturing of APIs for muscle relaxant and anti-flatulent applications.
- FBL delivers innovative enzymes used in manufacturing of active pharmaceutical ingredients and is involved in environmental solutions used for waste water treatment and management.
- The company also has legacy properties at Thane and Worli in Mumbai for which it realizes significant rental income.

Operational Revenue (INR Mn) & Operational EBITDA Margin (%)



Revenue Mix % (9M-FY22)





Mr. Sanjay Buch - Chairman (Independent Director)

- He holds a Bachelors Degree in Economics and Law and has over two decades of experience in wide spectrum of legal work.
- Currently, he is partner at Crawford Bayley & Co.
- An advocate and solicitor, specializing in business restructuring, mergers and acquisitions and is a member of various committees of the Board of Directors of the Company.



Mr. Krishna Datla (Promoter & Executive Vice Chairman)

- A Commerce Graduate from Mumbai University having around 20 years of experience in the industry
- A progressive thinker responsible for the decision making process and overseeing new businesses. He has infused a strong sense of global vision thereby opening the opportunities across International markets.



Mr. Satish Varma (Executive Director)

- In 1994, he joined the DIL group as the Executive Assistant to the then Managing Director. In this role he garnered extensive operational, management and legal experience across the full scope of the company. In 2003 he joined the Board of Directors of FBL.
- In addition to his Executive Board duties, he is also a member of the Stakeholder Relationship Committee.



Ms. Anupama Datla (Executive Director)

- She is a post-graduate in Biotechnology from the Mumbai University and a Science Graduate from the Boston College, USA. Joined FBL in 2006 and went on to join the board in 2007 as the Executive Director.
- She has taken executive leadership in R&D, quality control, and implementing safety policies and procedures across the organization.
- She is the author of various patents within the group, is in charge of introducing and implementing new technology platforms into the company and also spearheads the new business development.



Ms. Rajeshwari Datla (Non-Executive Director)

- A Science graduate having a rich experience in the Pharmaceutical Industry. She joined the board in 2005 as an additional director.



Mr. Vinayak Hajare (Non-Executive Independent Director)

- Qualified Masters degree holder in Financial management from Jamnalal Bajaj Institute of Management Studies.
- He has over three decades of work experience in areas such as Investment Banking and Corporate Finance.
- He has served as an Associate Director at Ernst and Young and has held several senior positions in companies like Caylor Bank, Credit Lyonnais, and Lazard India.




Dr. Gopakumar Nair (Non-Executive Independent Director)

- He has a Ph.D from National Chemical Laboratory (NCL), Diploma in Management & Patent Law and is Law graduate (LL.B) from Mumbai University.
- He is an Intellectual Property Rights Consultant and practicing Patent Attorney.
- He is also a practicing lawyer specialising in Mediation and Arbitration as well as in licensing and technology transfer. Further, has been associated with pharmaceutical industry for more than four decades as Director, Managing Director & Chairman of various public limited pharmaceutical companies.



Ms. Rajshree Ojha (Non-Executive Independent Director)

- Has over 28 years of experience in pharmaceutical industry including in R&D analytical development, technical/CMC documentation QC-QA-QM, regulatory compliance, and registration & marketing approvals globally.
- She has published many articles and research papers in reputed national and International Journals, she has also been awarded with various leadership awards.
- She is also an Adjunct Professor at KLE University, Mysore, and an Expert Member of Global Compliance Panel-DE.



Mr. Prashant Nagre, Managing Director

- Prashant Nagre is Managing Director of the company. Nearly three decades in the pharmaceuticals industry, he has in-depth experience across spheres encompassing the API business, production, Research and Development.
- At erstwhile DIL, Prashant headed strategy and day to day operations including Business Development, budgeting, manufacturing, R&D and allied activities. He holds a Master's in Management Sciences, and also a Post Graduate Diploma in International Trade (IIFT, New Delhi) besides a Degree in Pharmacy.

Awards and Recognitions



Best Workplaces™
in Biotechnology & Pharmaceuticals

Great Place To Work®
INDIA 2021



India Pharma Awards 2021



Pride of Maharashtra Awards 2021



India Pharma Awards 2018



Excellence in R&D – Development of new product/technology (Runner up)

Best Company of the Year - Excellence in Exports

Excellence in CSR

Excellence in Export Promotion

Pharma International Excellence



The Economic Times Inspiring CEOs 2021



Chief Strategy Officer Summit & Awards 2020



Business Excellence Awards 2019



Hindustan Times Thane Ratna Award 2020



Best Business Brands 2020

FBL Features in the Media

Forbes

Fermenta Biotech: Lucre in sheep's clothing

By Naini Thaker | Aug 22, 2019

While extracting Vitamin D3 from wool has been its mainstay, the firm is looking to move beyond its niche and expand into biotechnology



Coverage in Forbes India
Issue dated 30th August 2019



ET Now interview telecast on its morning prime time show on 6th January 2020

Fermenta Biotech Limited



TUESDAY, AUGUST 20, 2019



Managing in a VUCA World

Creating shared value in a VUCA world ensures business continuity

In a world wrought with the multitude of variables, such as a new geography with unfamiliar regulatory norms, can be done by acquiring know-how through internal and external sources:

Volatility: In a state of dynamic instability such as price fluctuations, it is imperative to make the following investments that match the risk of rapid changes:

- Devote time and resources to preparedness - stockpile inventory
- Use data analytics to minimize the unpredictability

Uncertainty: A lack of clarity for the future, like a potential competitor's entry into the market, can be dealt in the ways below:

- Maintain flexibility in your strategy
- Invest in information such as primary research and market reports

Complexity: Making sense of the multitude of variables, such as a new geography with unfamiliar regulatory norms, can be done by acquiring know-how through internal and external sources:

- Hiring in specialists in your human capital
- Collaborate with partners who know the environment

Ambiguity: In cases when precedents are unknown or in-existent, like when launching a new product outside your core competency in emerging markets, navigate through the fog by:

- Setting incremental and clear goals for employees
- Being open to new and divergent ideas
- Whatever the state your business is in, maintaining clear communication with all stakeholders is the key to sustainable growth.

Economic Times supplement
Dated 20th August 2019

THE TIMES OF INDIA

Help Protect Our Protectors: Fermenta Biotech Ltd. & Indchemie Health Specialities Pvt. Ltd. donate Vitamin D to 250,000 Maharashtra Police personnel

Mediawire | Jul 30, 2020, 12:15 PM IST



"Let hope be the antidote to fear. Let solidarity be the antidote to blame. Let our shared humanity be the antidote to our shared threat." - WHO Director-General's opening remarks at the media briefing on COVID-19 on 9th March 2020

Coverage of CSR activity in The Times of India
Dated 30th July 2020



mint

BRAND POST

FBL develops and files a patent application for an orally active COVID 19 drug



Mr. Prashant Nagre, CEO, Fermenta Biotech Limited

Mr. Prashant Nagre, CEO, FBL


3 min read | Updated: 19 Apr 2021, 06:21 PM IST

Brand Post

- This novel technology using green chemistry provides a sustainable, efficient and scalable form of treatment to fight against COVID-19.


Press release coverage in Mint
Dated 19th April 2021







Geographical Revenue Mix % (FY21) for Vit D3 and Other API



- R&D Centre and Registered Office
- Manufacturing Facility
- International Subsidiaries
- Regions Present

Kullu (Himachal Pradesh)

- Set up the Biotech plant in 1987 to manufacture Penicillin G Amidase and Acylase enzyme. A new bulk drug division in 2004 to manufacture various APIs like Vitamin D3, Phenylramidol HCl and Silicon Powder.
- This plant is certified by WHO-GMP, CDSCO-WC, USFDA, HACCP, ISO-9001, ISO-14001, ISO-45001, BRC, FSSC, FSMA, FAMI-QS, HALAL, KOSHER etc.



Dahej (Gujarat) – Vitamin D3

- Established a dedicated green field manufacturing facility in 2011 to primarily manufacture Vitamin D3.
- This plant is certified WHO-GMP, CDSCO-WC, HACCP, ISO-9001, ISO-14001, ISO-45001, BRC, FSSC, FSMA, FAMI-QS, HALAL, KOSHER etc.

Dahej (Gujarat) – Backward Integration for Cholesterol

- Cholesterol is the key raw material for manufacturing of Vitamin D3, which is derived from wool grease (by-product of sheep wool scouring).
- In 2019, FBL implemented backward integration for manufacturing cholesterol which will cover 100% requirements.



Accreditations & Certifications*



*Accreditations & Certifications are products / site specific



R&D

- Modern, fully equipped, DSIR approved Research & Development facility complemented by highly skilled and committed scientists.

- Providing integrated solutions, processes and products for Biotech and Active Pharmaceutical Ingredients (API)

- API R&D, combined with expertise on photochemistry, chromatography and multi-step process development skills

- Biotech R&D has got wide experience in the areas of bacterial fermentation, enzyme expression, immobilization platforms and process development in various enzymatic applications

- Dedicated formulation development lab which currently focuses on solutions for various value-added formats in the nutrition basket, including premix (liquids and solids), and personal care portfolio



Driven by the Discover, Develop & Deliver philosophy



Quality



- Quality Assurance: Responsible for implementing quality systems, regulatory audits (national and international including customer and GMP) and releasing all manufactured products

- Regulatory Affairs: Ensures compliance with national and international regulatory requirements

- Quality Control: Responsible for all analysis, from analytical support to validations



Irradiation Process Of Pro Vitamin D



An Improved Process To Synthesize 5-(3-Pyridyl)-2, 2'-Bithiophene (Sensitizer)



Improved Cost Effective Process for Synthesis of Vitamin D3 and its Analogue Calcifediol from Ergosterol



Synthesis of 5-(3-pyridyl)-2,2'-Bithiophene (Sensitizer)



Novel Method For Synthesizing 25-OH Cholesterol/Calcifediol From Phytosterol



Improved Photochemical Synthesis Of Vitamin D3 Using Sensitizer



Synthesis of Cholesterol and Vitamin D3 From Phytosterols



An Efficient Method for Synthesis of 5-(3-pyridyl)-2,2'-Bithiophene (Sensitizer)

New patents filed in 2021



Enzymatic Synthesis of Molnupiravir Intermediate




Chemo - Enzymatic Process for Synthesis of Molnupiravir



Scalable Two Step Synthesis of Molnupiravir




A one step process for the enzymatic synthesis of semisynthetic β -lactam antibiotics (Penmox)



BUSINESS OVERVIEW

About Vitamin D3

- Vitamin D3 (Cholecalciferol) is a fat-soluble vitamin, responsible for calcium absorption in the body.
- Vitamin D3 is produced by the body when skin is exposed to UV-B rays from the sun. Vitamin D can also be obtained from dietary sources.
- 80-90% of the Indian population¹, and over 1 billion people worldwide², suffer from low Vitamin D levels – due to an indoors lifestyle and poor diet.




For Humans

- Vitamin D has been linked to a multitude of health benefits such as general health and wellbeing, bone and mental health as well as management and prevention of certain lifestyle disorders such as diabetes and cardiovascular disease.
- Vitamin D has also been shown to play an important role in immunity and protection against respiratory infections.³
- Recent research has suggested that Vitamin D supplementation may reduce the risk of COVID-19 complications. Citing Vitamin D as a potent immune-modifying micronutrient, studies have advocated supplementation and called on governments to increase recommended levels.^{6,7,8}

For Animals

- Vitamin D has been seen to improve bone strength and density as well as fertility. It has the potential to enhance yield and quality of milk, meat and eggs.^{4,5}




References:


1. J Family Med Prim Care. 2018;7(2):324–330.
2. J Pharmacol Pharmacother. 2012;3(2):118–126.
3. Mayo Clin Proc. 2013;88(7):720–755.
4. J Dairy Sci. 1974 Sep;57(9):985-91.
5. Poultry Sci. 1995 Dec;74(12):1919-34.
6. Aliment Pharmacol Ther, 51: 1434-1437., April 2020
7. TILDA, Irish Medical Journal, April 2020
8. Nutrients. 2020;12(4):988., April 2020

- FBL is a leader in manufacturing Vitamin D3, and has the distinction of being the only organization in India to manufacture Vitamin D3
- The company has a Non-China dependent supply chain.

CAGR Growth FY15 to FY21



Vitamin D3 Revenue (INR Mn)



Unique

One of three CEP-certified companies worldwide



Pioneering

Use of proprietary technology to manufacture Vitamin D3 API



Knowledge Capital

55 years of experience and the proficiency in manufacturing Vitamin D3 with a base of over 350+ customers



Scale

It is among the top three producers of Vitamin D3 API in the world



One Stop Shop

It manufactures Vitamin D3 for various applications (human and veterinary healthcare, animal feed)



Integrated

Superior quality and cost effectiveness from backward integrated manufacturing operations





Standardized

Products and manufacturing facilities certified by various global health regulatory like US-FDA (FFRN), American Vegetarian Association, FAMI-QS, WHO-GMP etc.

Manufacturing Process and Applications


Backward Integrated Manufacturing Process



--- Currently processing to manufacture Vitamin D3 from cholesterol

- - - Completed backward integration to manufacture cholesterol

Vitamin D3 Applications



Heritage of innovation in enzymes



One-stop Destination for Green Chemistry

FBL's core expertise spans from microbial screening, fermentation, immobilization, biocatalysis, enzyme-mediated antibiotic synthesis to API intermediates & APIs

FBL is a pioneer in the development and production of fermentation-based Penicillin G Amidase enzyme (PGA) and commercialized immobilized enzymes in India

The Company is also actively working towards promoting CAL B lipase in niche applications which can revolutionize various critical API processes

FBL possesses patented technology for enzymatic synthesis of Molnupiravir

APIs & Other intermediaries

- For over 25 years, FBL is a trusted and reliable source of Phenylamidol HCl (muscle relaxant) & Silicon Powder (anti-flatulent) APIs.



Environmental Solutions

- FBL's Environmental Solutions provide unique advantages in waste water treatment and management through integrated biotechnology.



Fish Oil Cholesterol

- As an extension to its product portfolio, FBL has started manufacturing cholesterol from fish oil for applications in the aquaculture market (specifically the shrimp feed segment), which was commercialised in FY21



Real Estate

- 45 Acres of freehold land at Takawe, Pune
- ~10,000 sq. ft. leased area at Worli, Mumbai
- ~200,000 sq. ft. leasable area in Thane One
- 6 Acres of freehold land at Thane One
- Approximate market value of real estate is ~500 Cr
- Real estate lease rentals help sufficiently service the real estate debt





Monetization of Thane land: Development deal structure



Property

- As part of its legacy property, Fermenta owns ~6.5 acres of freehold land in Thane
- This is partly developed by constructing Thane One, an IT/ITES Building

Project

- Fermenta has signed Binding Term Sheet with Mextech and granted development rights for construction of residential-cum-commercial buildings in the balance portion of land
- Project completion is expected within 6 years of signing the Definitive Agreement
- Revenues expected to be generated in a staggered manner post launch of the Project

Development partners and their role

- Development partners: Mextech Property Developers LLP, incorporated by the promoters of Nandivardhan Constructions Private Limited and RRC Ventures Private Limited
- Development partners are solely responsible for obtaining approvals, permissions, construction, OC and sales
- They will solely bear all the costs of approvals, permissions, premiums and construction in the Project

Ownership

- Fermenta to receive 120,000 sq. ft. carpet area (as per RERA) of residential construction along with amenities as its share of premises in the Project, and the balance area to be owned by development partners
- Development partners not to mortgage the land or Fermenta's premises for obtaining funding from banks/financial institutions for the Project
- Fermenta continues to solely own the already constructed Thane One building

Expanding Our Nutraceutical Basket



- From single Vitamin D3 to multi-vitamin, the company aims to widen its nutraceuticals ingredients basket within the next 5 years
- Developing new technologies enabling FBL to get into value-added ingredients, improving stability, bioavailability and scalability
- In this journey, the company is exploring inorganic opportunities as well
- Distribution network already built for catering to an expanded nutraceutical basket

Single-vitamin to multi-vitamin

Aim to broaden vitamin product bouquet to be more palatable to customers

Multi-vitamins to Nutraceuticals

Target initially by penetrating functional food and nutraceutical supplements. Further strategically adding core nutraceuticals for tackling common health problems and adding medical nutraceuticals for infant feeding, chronic ailments, boosting immunity, etc.

Customer Segments



Infants



Adulthood



Childhood & Adolescence



Elderly

Nutraceutical Product Pipeline



Vitamin D3 and its various formats for
Pharmaceuticals
Dietary & Nutritional Supplements
Food
Feed
Veterinary Science
Rodenticide

Variants of Fat soluble vitamins
Vitamin A
Vitamin E
Vitamin D2
Vitamin K1

Nutrition portfolio
Fortified Rice Kernel
Smart Minerals
Customized Premixes
Pre and Pro - Biotics



Products Recently Launched

Vitamin D3 500
Feed Grade (new
variant from
Fermenta
Biotech GmbH)

Natural
Astaxanthin

Omega - 3
Fatty Acids

Vitamin
AD2 for oil
fortification

Fortified
Rice Kernel

Vitamin K1

Customized
premix

Q1
FY21

Q3
FY21

Q3
FY21

Q1
FY22

Q1
FY23

Q2
FY23

Q3
FY23

Growth Drivers

Internal Factors

- Strong manufacturing capabilities with enhanced capacity utilizations to meet YoY production targets
- Enhancing control and reduced dependence by backward integration
- Sales footprint in 60+ countries spread across the globe
- Expanding into value added formats of vitamins like A, E, D2, manufacturing Vitamin K and further focus on development of smart minerals, novel anti-oxidants, customized premixes, pre and pro-biotics etc.
- Setting up plant at Sayakha, Gujarat for enhancing nutraceutical portfolio.

External Factors

- Increased prescription market for Vitamin D3 formulations
- Growing need for applications in the form of tablets, capsules and syrups
- Government guidelines related to use of Vitamin D in food fortification
- Significant portion of global population is Vitamin D deficient or insufficient
- Understanding of Vitamin D benefits has moved beyond bone & joint health to management of lifestyle disorder as well as general health, wellbeing and immunity





Enhanced Focus

Exiting of non-core business activities and laying long term emphasis on expanding the Nutraceutical business.



Capital Allocation Plans

All future capital allocation will be focused towards Nutraceuticals business.



Real Estate Business

The company has taken steps towards monetizing these assets at appropriate valuations and there are no plans to infuse any further capital in real estate.



Debt

The company has a long term debt of approximate INR 128 Cr with a low average cost of debt at ~ 7% pa. Around 55% of the long term debt is towards the real estate business where the lease rentals are self sufficient enough to take care of the principal repayment and interest.



Focus to reduce working capital

The company's increase in working capital was primarily due to the increased inventory levels. This was a strategic move to secure key raw material requirements. Going ahead the working capital is expected to significantly reduce.



Dividend Policy

The company strives to have a prudent dividend policy with a healthy balance between shareholders' returns and organizational requirement for future growth.




Capacity Expansion

Around 20% capacity expansion for Vitamin D3 in Q2 FY22 with INR 30 Cr investment

Risk mitigation measures for COVID-19

Business Continuity Planning

Safeguarding Human Capital





INDUSTRY OVERVIEW



Vitamin D Industry



- The Vitamin D market is estimated to account for about USD 1.1 billion in 2019 and is projected to reach a value of nearly USD 1.7 billion by 2025, growing at a CAGR of 7.0% from 2019 to 2025.
- Around the world 1 in 3 women and 1 in 5 men over the age of 50 will suffer an osteoporotic fracture. In fact, a bone will break every 3 seconds because of this disease. Osteoporotic fractures are a result of osteoporosis, a condition in which the bones become more fragile due to bone deterioration or low bone mass.
- Numerous studies across various regions of India indicate that approximately 70-90% of apparently healthy population is Vitamin D deficient.
- According to the 2019 Alltech Global Feed Survey, Asia Pacific is home to several of the top 10 feed-producing countries, including China, India, and Japan; and accounted for more than 36.0% of the world's feed tonnage. China dominated as the top feed-producing country in the world, with 187.9 million metric tons (207.1 million tons).
- Data shows the Vitamin D3 market saw an 80.5 per cent jump from 2014 levels, whereas the Vitamin D combinations products market size witnessed a 141.5 per cent jump.

Market size of vitamins and CAGR			
	MAT Value July 2014 (INR Bn)	MAT Value July 2018 (INR Bn)	5-year value CAGR (%)
Vitamin D3 market size	2.98	5.38	15.9
Overall market of vitamins	39.28	58.08	8.14

Market shares of vitamin segment	
Vitamin sub-segment	Market share in overall vitamin segment (%)
Multivitamins + Minerals	22.28
Vitamin D3	9.27
Plain Vitamin B Complex	5.45



Source: marketsandmarkets, iofbonehealth.org, Business Standard, Moneycontrol

Top Vitamin D3 Brands		
Brand	Company	Market share (%)
Uprise D3	Alkem Laboratories	12.17
Calcirol	Cadila Pharma	11.49
Arachitol	Abbott India	6.06
Depura	Sanofi	5.19
D3 Must	Mankind Pharma	4.93

*“The goal should be to raise 25(OH)D concentrations above 40-60 ng/mL (100-150 nmol/L). For treatment of people who become infected with COVID-19, higher vitamin D3 doses might be useful.” – Dr. William Grant**

"If you're deficient in vitamin D, that does have an impact on your susceptibility to infection. I would not mind recommending, and I do it myself, taking vitamin D supplements.” – Dr. Anthony Fauci, Director, National Institute of Allergy and Infectious Diseases^

*Nutrients. 2020 Apr 2;12(4):988.

^Business Insider, 12th September 2020

Internal and Emergency Medicine
<https://doi.org/10.1007/s11739-021-02902-w>

IM - ORIGINAL

Vitamin D deficiency is associated with higher risks for SARS-CoV-2 infection and COVID-19 severity: a retrospective case–control study

Ariel Israel¹ · Assi Cicurel^{1,2} · Ilan Feldhamer¹ · Felicia Stern³ · Yosef Dror³ · Shmuel M. Givone⁴ · David Gillis⁵ · David Strich⁶ · Gil Lavie^{1,7}

Received: 17 September 2021 / Accepted: 20 November 2021
 © The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI) 2021

Abstract
 Robust evidence of whether vitamin D deficiency is associated with COVID-19 infection and its severity is still lacking. The aim of the study was to evaluate the association between vitamin D levels and the risks of SARS-CoV-2 infection and severe disease in those infected. A retrospective study was carried out among members of Clalit Health Services (CHS), the largest healthcare organization in Israel, between March 1 and October 31, 2020. We created two matched case–control groups of individuals for which vitamin D levels and body mass index (BMI) were available before the pandemic: group (A), in which 41,757 individuals with positive SARS-CoV-2 PCR tests were matched with 417,570 control individuals without evidence of infection, and group (B), in which 2533 patients hospitalized in severe condition for COVID-19 were matched with 2533 patients who were tested positive for SARS-CoV-2, but were not hospitalized. Conditional logistic models were fitted in each of the groups to assess the association between vitamin D levels and outcome. An inverse correlation was demonstrated between the level of vitamin D and the risks of SARS-CoV-2 infection and of severe disease in those infected. Patients with very low vitamin D levels (<30 nmol/L) had the highest risks for SARS-CoV-2 infection and also for severe COVID-19 when infected—OR 1.246 [95% CI 1.210–1.304] and 1.513 [95% CI 1.230–1.861], respectively. In this large observational population study, we show a significant association between vitamin D deficiency and the risks of SARS-CoV-2 infection and of severe disease in those infected.

Lower Vitamin D levels may have an impact on the incidence and severity of COVID-19 infection.

Received: 12 January 2021 | Accepted: 26 July 2021
 DOI: 10.1111/irp.14675

META-ANALYSIS
 Infectious Diseases

THE INTERNATIONAL JOURNAL OF
 CLINICAL PRACTICE WILEY

The role of vitamin D in the age of COVID-19: A systematic review and meta-analysis

Correspondence
 Amir Shamshirian, Gastrointestinal Cancer Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
 Email: shamshirian.amir@gmail.com

Daniial Shamshirian, Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
 Email: shamshirian@sbmu.ac.ir

Abstract
Background: Evidence recommends that vitamin D might be a crucial supportive agent for the immune system, mainly in cytokine response regulation against COVID-19. Hence, we carried out a systematic review and meta-analysis in order to maximise the use of everything that exists about the role of vitamin D in the COVID-19.

There is about 3 times higher chance of getting infected with SARS-CoV-2 among Vitamin-D-deficient individuals and about 5 times higher probability of developing severe disease in Vitamin-D-deficient patients

nutrients

Systematic Review
COVID-19 Mortality Risk Correlates Inversely with Vitamin D3 Status, and a Mortality Rate Close to Zero Could Theoretically Be Achieved at 50 ng/mL 25(OH)D3: Results of a Systematic Review and Meta-Analysis

Lorenz Borsche^{1,*}, Bernd Glauner² and Julian von Mendel³

¹ Independent Researcher, D-69117 Heidelberg, Germany
² Independent Researcher, D-72076 Tübingen, Germany; bgl@oellprobe.de
³ Artificial Intelligence, IU International University of Applied Sciences, D-99084 Erfurt, Germany; pub@derjulian.net
 * Correspondence: borsche@gmx.de

Low Vitamin D3 is a predictor rather than just a side effect of the infection

PLOS ONE

RESEARCH ARTICLE
Pre-infection 25-hydroxyvitamin D3 levels and association with severity of COVID-19 illness

Amiel A. Dror^{1,2,*}, Nicole Morozov³, Amani Daoud^{1,2}, Yoav Namir², Orly Yakir⁴, Yair Shachar¹, Mark Lifshitz⁵, Ella Segal^{1,2}, Lior Fisher^{1,2}, Matti Mizrahi^{1,2}, Netanel Eisenbach^{1,2}, Doaa Rayan^{1,2}, Maayan Gruber^{1,2}, Amir Bashkin^{2,6}, Edward Kaykov^{2,7}, Masad Barhoum⁸, Michael Edelstein⁸, Eyal Sela^{1,2}


¹ Department of Otolaryngology, Head and Neck Surgery, Galilee Medical Center, Nahariya, Israel, ² Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel, ³ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ⁴ Statistical Analysis Division, Galilee Medical Center, Nahariya, Israel, ⁵ Computer Data Division, Galilee Medical Center, Nahariya, Israel, ⁶ Endocrinology Unit, Galilee Medical Center, Nahariya, Israel, ⁷ Geriatric Medicine Department, Galilee Medical Center, Nahariya, Israel, ⁸ Galilee Medical Center, Nahariya, Israel

* amiekdror@gmail.com

Abstract

Among hospitalized COVID-19 patients, pre-infection deficiency of Vitamin D was associated with increased disease severity and mortality.

Vitamin D3 500 Animal Feed Price Trend



Source: feedinfo.com



*As per calendar year

Nutraceutical Industry



- The USA, Japan and Europe account for more than 90% of the total global nutraceutical market.
- North America nutraceuticals market is a mature market and is likely to progress at a CAGR of over 7.8% from 2016 to 2024. Increasing utilization of functional food and beverages by the baby boomer population in North America is expected to augment market growth.
- Central & South America accounted for a market share of 7.2% in 2016 and is projected to ascend at a CAGR of 9.0% from 2017 to 2025 in terms of revenue owing to growing demand for nutraceuticals in Brazil.
- Dietary supplements segment is expected to ascend at a CAGR of over 9.7% from 2017 to 2025 on account of rising product demand from Brazil, China, India, South Korea, Poland, and Mexico.
- Focus of nutraceutical players is now shifting towards developing economies, especially those across Asia Pacific, including India.
- In 2017, the Indian market held only 2% market share of the global nutraceutical market and its estimated valuation stands at around \$5 billion as of 2019. It is expected to reach \$11 billion by 2023, increasing at a CAGR of 21%. By 2023, India is also expected to hold at least 3.5% market share of the global market.
- Asia Pacific is predicted to ascend at the fastest CAGR of 9.9% over the forecast period on account of rapid growth of the market in China, Japan, and India.

Source: Business Standard, ASSOCHAM Nutraceuticals Report 2018



AL GROWTH

Manufacturing
Chemicals

22.10

24.78

FINANCIAL OVERVIEW

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

2001

2000

1999

1998

1997

1996

1995

1994

1993

1992

1991

1990

1989

1988

1987

1986

1985

1984

1983

1982

1981

1980

1979

1978

1977

1976

1975

1974

1973

1972

1971

1970

1969

1968

1967

1966

1965

1964

1963

1962

1961

1960

1959

1958

1957

1956

1955

1954

1953

1952

1951

1950

1949

1948

1947

1946

1945

1944

1943

1942

1941

1940

1939

1938

1937

1936

1935

1934

1933

1932

1931

1930

1929

1928

1927

1926

1925

1924

1923

1922

1921

1920

1919

1918

1917

1916

1915

1914

1913

1912

1911

1910

1909

1908

1907

1906

1905

1904

1903

1902

1901

1900

1899

1898

1897

1896

1895

1894

1893

1892

1891

1890

1889

1888

1887

1886

1885

1884

1883

1882

1881

1880

1879

1878

1877

1876

1875

1874

1873

1872

1871

1870

1869

Historical Standalone Income Statement



PARTICULARS (INR Mn)	9M-FY22	FY21	FY20	FY19
Operational Revenue	2,933	3,728	3,005	4,047
Total Expenses	2,359	2,791	2,311	2,634
Operational EBITDA	574	937	694	1,413
<i>Operational EBITDA Margin (%)</i>	19.57%	25.13%	23.09%	34.91%
Other Income	45	66	123	123
Depreciation	176	190	149	119
Finance Cost	127	181	193	206
PBT	316	632	475	1,211
Tax	104	112	(162)	107
PAT	212	520	637	1,104
<i>PAT Margins (%)</i>	7.23%	13.95%	21.20%	27.28%
Other Comprehensive Income	0	(0.4)	18	(15)
Total Comprehensive Income	212	519	655	1,089
Diluted EPS (INR)	7.31	17.92	21.96	38.24*

*Adjusted EPS post bonus issue in the proportion of 2:1

Standalone Balance Sheet (Ind-AS)



PARTICULARS (INR Mn)	H1-FY22	FY21	FY20
Equity	3,857	3,704	3,126
a) Equity share capital	144	144	144
b) Other equity	3,713	3,560	2,982
Liabilities			
Non-current liabilities	1,128	1,192	1,115
a) Financial liabilities	-		
i) Borrowings	1,031	1,104	1,018
ii) Lease liabilities	43	35	45
iii) Other financial liabilities	5	5	6
b) Provisions	47	45	41
d) Other non-current liabilities	2	3	5
Current Liabilities	1,891	1,929	1,855
a) Financial liabilities	-		
i) Borrowings	1,171	1,188	1,043
ii) Lease liabilities	11	12	11
ii) Trade payables	516	457	472
iii) Other financial liabilities	134	184	297
b) Provisions	6	8	6
c) Other current liabilities	50	76	23
d) Current tax liabilities (Net)	3	3	3
TOTAL EQUITY AND LIABILITIES	6,876	6,825	6,096

PARTICULARS (INR Mn)	H1-FY22	FY21	FY20
Assets			
Non-current Assets	3,806	3,745	3,272
a) Property, plant and equipment	1,901	1,538	1,040
b) Capital work-in-progress	226	527	671
c) Right of use assets	166	147	162
d) Investment property	683	682	707
e) Goodwill	41	41	41
f) Other intangible assets	78	88	18
g) Intangible assets under development	41	42	37
h) Investments	-		
i) Investments in subsidiaries	127	127	8
i) Financial assets	-		
i) Investments	3	2	3
ii) Loans	-	-	2
iii) Others financial assets	34	22	41
j) Deferred tax assets (Net)	340	381	381
k) Non-current tax assets (Net)	127	113	91
l) Other non-current assets	39	35	70
Current Assets	3,070	3,080	2,824
a) Inventories	1,271	1,328	1,135
b) Financial assets	-		
i) Trade receivables	1,054	961	774
ii) Cash and cash equivalents	112	136	68
iii) Bank balances other than (iii) above	231	277	256
iv) Loans	-	48	213
v) Other financial assets	50	80	129
c) Other current assets	352	250	249
TOTAL ASSETS	6,876	6,825	6,096

Historical Consolidated Income Statement



PARTICULARS (INR Mn)	9M-FY22	FY21	FY20	FY19
Operational Revenue	3,024	3,773	2,929	4,047
Total Expenses	2,587	2,956	2,277	2,558
Operational EBITDA	437	817	652	1,489
Operational EBITDA Margin (%)	14.45%	21.65%	22.26%	36.79%
Other Income	53	82	123	124
Depreciation	191	203	150	119
Finance Cost	127	180	191	207
PBT	172	516	434	1,287
Tax	99	91	(161)	108
PAT before Associates & Joint Venture	73	425	595	1,179
Share of Loss of Associates & Joint Venture	-	-	-	(4)
Non-controlling interests	5	30	-	-
PAT	78	455	595	1,175
PAT Margins (%)	2.58%	12.06%	20.31%	29.03%
Other Comprehensive Income	7	(2)	17	(15)
Total Comprehensive Income	80	423	612	1,160
Diluted EPS (INR)	2.68	15.69	20.53	40.70*

*Adjusted EPS post bonus issue in the proportion of 2:1

Consolidated Balance Sheet (Ind-AS)



PARTICULARS (INR Mn)	H1-FY22	FY21	FY20
Equity	3,721	3,603	3,094
a) Equity share capital	144	144	144
b) Other equity	3,581	3,462	2,950
c) Non-controlling interests	(4)	(3)	0.1
Liabilities			
Non-current liabilities	1,110	1,175	1,097
a) Financial liabilities	-		
i) Borrowings	1,031	1,105	1,018
ii) Lease liabilities	25	17	27
iii) Other financial liabilities	5	5	6
b) Provisions	47	45	41
c) Other non-current liabilities	2	3	5
Current Liabilities	2,069	2,093	1,946
a) Financial liabilities	-		
i) Borrowings	1,171	1,188	1,043
ii) Lease liabilities	11	12	11
ii) Trade payables	688	621	564
iii) Other financial liabilities	134	184	297
b) Provisions	9	7	5
c) Other current liabilities	53	77	23
d) Current tax liabilities (Net)	3	3	3
TOTAL EQUITY AND LIABILITIES	6,900	6,871	6,137


PARTICULARS (INR Mn)	H1-FY22	FY21	FY20
Assets			
Non-current Assets	3,830	3,775	3,297
a) Property, plant and equipment	1,901	1,539	1,040
b) Capital work-in-progress	226	527	671
c) Right of use assets	149	129	143
d) Investment property	688	687	713
e) Goodwill	108	107	41
f) Other intangible assets	150	168	65
g) Intangible assets under development	41	42	37
h) Financial assets	-		
i) Investments	3	3	3
ii) Loans	-	-	2
iii) Others financial assets	34	22	40
i) Deferred tax assets (Net)	364	403	381
j) Non-current tax assets (Net)	127	113	91
k) Other non-current assets	39	35	70
Current Assets	3,070	3,096	2,840
a) Inventories	1,624	1,623	1,286
b) Financial assets	-		
i) Trade receivables	703	680	698
ii) Cash and cash equivalents	143	168	75
iii) Bank balances other than (iii) above	231	277	256
iv) Loans	-	48	213
v) Other financial assets	3	35	63
c) Other current assets	366	265	249
TOTAL ASSETS	6,900	6,871	6,137




Historical Consolidated Financial Performance




Operational Revenue (INR Mn)




Operational EBITDA (INR Mn) & Margins (%)




PAT (INR Mn) & Margins (%)




RoCE & RoE (%)



Working Capital Days



Net Debt to Equity (x)



No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management Fermenta Biotech Limited ("Company" or "FBL"), which are expressed in good faith and in their opinion reasonable, including those relating to the Company's general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. This presentation does not constitute an offer or invitation to purchase or subscribe for any securities in any jurisdiction, including the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of our securities may be offered or sold in the United States, without registration under the U.S. Securities Act of 1933, as amended, or pursuant to an exemption from registration there from.

This presentation is confidential and may not be copied or disseminated, in whole or in part, and in any manner.

Valorem Advisors Disclaimer:

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review.



For further information please contact our Investor Relations Representatives:

Mr. Anuj Sonpal

Valorem Advisors

Tel: +91-22-4903-9500

Email: fermenta@valoremadvisors.com